TScan Therapeutics’ (TCRX) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Tuesday morning,RTT News reports. The firm currently has a $7.00 price objective on the stock.

Several other research firms also recently weighed in on TCRX. HC Wainwright reduced their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Wall Street Zen upgraded shares of TScan Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.80.

TScan Therapeutics Trading Up 3.7%

Shares of TScan Therapeutics stock opened at $1.67 on Tuesday. The firm has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.68. The company has a market cap of $94.51 million, a P/E ratio of -1.53 and a beta of 0.99. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.55 and a current ratio of 8.55.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. As a group, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the business’s stock in a transaction on Tuesday, May 20th. The stock was bought at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the acquisition, the insider owned 7,946,141 shares in the company, valued at approximately $9,535,369.20. The trade was a 17.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

A number of hedge funds have recently bought and sold shares of TCRX. JPMorgan Chase & Co. raised its holdings in TScan Therapeutics by 109.9% in the 4th quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company’s stock valued at $203,000 after acquiring an additional 34,951 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after buying an additional 6,550 shares during the period. Wells Fargo & Company MN grew its stake in shares of TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after buying an additional 5,694 shares during the period. Barclays PLC grew its stake in shares of TScan Therapeutics by 16.3% in the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after buying an additional 9,441 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock valued at $851,000 after buying an additional 145,731 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.